190 related articles for article (PubMed ID: 9488196)
1. Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection?
Tulenko TN; Laury-Kleintop L; Walter MF; Mason RP
Int J Cardiol; 1997 Dec; 62 Suppl 2():S55-66. PubMed ID: 9488196
[TBL] [Abstract][Full Text] [Related]
2. The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection.
Tulenko TN; Sumner AE; Chen M; Huang Y; Laury-Kleintop L; Ferdinand FD
Am Heart J; 2001 Feb; 141(2 Suppl):S1-11. PubMed ID: 11174352
[TBL] [Abstract][Full Text] [Related]
3. Atheroprotection with amlodipine: cells to lesions and the PREVENT trial. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial.
Tulenko TN; Brown J; Laury-Kleintop L; Khan M; Walter MF; Mason RP
J Cardiovasc Pharmacol; 1999; 33 Suppl 2():S17-22. PubMed ID: 10071259
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence.
Mason RP
Atherosclerosis; 2002 Dec; 165(2):191-9. PubMed ID: 12417269
[TBL] [Abstract][Full Text] [Related]
5. Effects of the calcium channel blocker amlodipine on serum and aortic cholesterol, lipid peroxidation, antioxidant status and aortic histology in cholesterol-fed rabbits.
Turgan N; Habif S; Kabaroğlu CG; Mutaf I; Ozmen D; Bayindir O; Uysal A
J Biomed Sci; 2003; 10(1):65-72. PubMed ID: 12566988
[TBL] [Abstract][Full Text] [Related]
6. Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers.
Schachter M
Int J Cardiol; 1997 Dec; 62 Suppl 2():S85-90. PubMed ID: 9488199
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of atherosclerotic plaque stabilization for a lipophilic calcium antagonist amlodipine.
Mason RP
Am J Cardiol; 2001 Nov; 88(10A):2M-6M. PubMed ID: 11705416
[TBL] [Abstract][Full Text] [Related]
8. Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection.
Eickelberg O; Roth M; Block LH
Int J Cardiol; 1997 Dec; 62 Suppl 2():S31-7. PubMed ID: 9488193
[TBL] [Abstract][Full Text] [Related]
9. Influence of serum cholesterol on atherogenesis and intimal hyperplasia after angioplasty: inhibition by amlodipine.
Kahn MB; Boesze-Battaglia K; Stepp DW; Petrov A; Huang Y; Mason RP; Tulenko TN
Am J Physiol Heart Circ Physiol; 2005 Feb; 288(2):H591-600. PubMed ID: 15388506
[TBL] [Abstract][Full Text] [Related]
10. Calcium channel blockers: do they have pleiotropic effects on atherosclerosis?
Pérez IF
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S96-9. PubMed ID: 10854088
[TBL] [Abstract][Full Text] [Related]
11. Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy.
Jukema JW; van der Hoorn JW
Expert Opin Pharmacother; 2004 Feb; 5(2):459-68. PubMed ID: 14996641
[TBL] [Abstract][Full Text] [Related]
12. Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: evidence from clinical trials and basic scientific research.
Mason RP
Cerebrovasc Dis; 2003; 16 Suppl 3():11-7. PubMed ID: 12740551
[TBL] [Abstract][Full Text] [Related]
13. Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin.
Orekhov AN; Tertov VV; Sobenin IA; Akhmedzhanov NM; Pivovarova EM
Int J Cardiol; 1997 Dec; 62 Suppl 2():S67-77. PubMed ID: 9488197
[TBL] [Abstract][Full Text] [Related]
14. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine.
Mason RP; Marche P; Hintze TH
Arterioscler Thromb Vasc Biol; 2003 Dec; 23(12):2155-63. PubMed ID: 14512371
[TBL] [Abstract][Full Text] [Related]
15. Calcium antagonists and atherosclerosis.
Schachter M
Int J Cardiol; 1997 Dec; 62 Suppl 2():S9-15. PubMed ID: 9488190
[TBL] [Abstract][Full Text] [Related]
16. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
Herbette LG; Vecchiarelli M; Sartani A; Leonardi A
Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437
[TBL] [Abstract][Full Text] [Related]
17. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine.
Chen L; Haught WH; Yang B; Saldeen TG; Parathasarathy S; Mehta JL
J Am Coll Cardiol; 1997 Aug; 30(2):569-75. PubMed ID: 9247534
[TBL] [Abstract][Full Text] [Related]
18. Excess membrane cholesterol alters calcium movements, cytosolic calcium levels, and membrane fluidity in arterial smooth muscle cells.
Gleason MM; Medow MS; Tulenko TN
Circ Res; 1991 Jul; 69(1):216-27. PubMed ID: 2054935
[TBL] [Abstract][Full Text] [Related]
19. Effect of serum withdrawal on the contribution of L-type calcium channels (CaV1.2) to intracellular Ca2+ responses and chemotaxis in cultured human vascular smooth muscle cells.
Patel MK; Clunn GF; Lymn JS; Austin O; Hughes AD
Br J Pharmacol; 2005 Jul; 145(6):811-7. PubMed ID: 15880143
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of plaque stabilization for a charged calcium channel blocker in coronary artery disease.
Mason RP
Pharmacotherapy; 2001 Sep; 21(9 Pt 2):209S-215S. PubMed ID: 11560191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
